NexImmune Expands Executive Team with Appointments of Chief Medical Officer and Chief Financial Officer
09 janv. 2020 07h30 HE
|
NexImmune, Inc.
GAITHERSBURG, Md., Jan. 09, 2020 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation...
NexImmune Receives IND Clearance for Phase 1/2 Trial in Relapsed / Refractory Multiple Myeloma
19 déc. 2019 07h30 HE
|
NexImmune, Inc.
IND clearance enables commencement of clinical trial to evaluate NEXI-002 in Multiple Myeloma patients who have failed >3 previous lines of therapyFDA action represents the Company’s second IND...
NexImmune Appoints Sol Barer as Chairman of the Board of Directors
16 déc. 2019 07h30 HE
|
NexImmune, Inc.
GAITHERSBURG, Md., Dec. 16, 2019 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation...
NexImmune Management to Present at Upcoming Conferences
02 déc. 2019 07h30 HE
|
NexImmune, Inc.
GAITHERSBURG, Md., Dec. 02, 2019 (GLOBE NEWSWIRE) -- NexImmune, a clinical stage immunotherapy company developing novel T cell therapies, announced that Scott Carmer, Neximmune’s Chief Executive...
NexImmune Receives IND Clearance for Phase 1/2 Trial in Acute Myeloid Leukemia / Myelodysplastic Syndrome
31 oct. 2019 07h30 HE
|
NexImmune, Inc.
IND clearance enables commencement of clinical trial to evaluate NEXI-001 in AML/MDS patients with relapsed disease after allogeneic stem cell transplantIND clearance validates Company’s Artificial...
NexImmune Management to Present at the Jefferies Healthcare Conference
04 juin 2019 09h47 HE
|
NexImmune, Inc.
GAITHERSBURG, Md., June 04, 2019 (GLOBE NEWSWIRE) -- NexImmune, an emerging leader in the field of antigen-directed immunotherapy, today announced that Scott Carmer, NexImmune’s Chief Executive...
Multiple Myeloma Research Foundation (MMRF) Venture Philanthropy Fund Invests in NexImmune to Advance Novel Immunotherapy Candidate Into Clinical Trials
29 avr. 2019 07h30 HE
|
NexImmune, Inc.
GAITHERSBURG, Md. and NORWALK, Conn., April 29, 2019 (GLOBE NEWSWIRE) -- NexImmune and the Multiple Myeloma Research Foundation (MMRF) have entered into a partnership to advance a promising new...
NexImmune Management to Present at Upcoming Conferences
05 avr. 2019 06h30 HE
|
NexImmune, Inc.
GAITHERSBURG, Md., April 05, 2019 (GLOBE NEWSWIRE) -- NexImmune, an emerging leader in the field of antigen-directed immunotherapy, today announced that Scott Carmer, Neximmune’s Chief Executive...
NexImmune Granted Key US Patent for Core E+E Technology
11 déc. 2018 08h00 HE
|
NexImmune, Inc.
GAITHERSBURG, Md., Dec. 11, 2018 (GLOBE NEWSWIRE) -- NexImmune, an emerging leader in the field of antigen-directed immunotherapy, today announced that the United States Patent and Trademark Office...
NexImmune Completes Sr. Leadership Team with New VP Hires
04 déc. 2018 08h00 HE
|
NexImmune, Inc.
Naimish Pandya, MD assumes role of VP & Head, Clinical DevelopmentAlex Matschiner, MS ChE assumes role of VP, Protein Process Development GAITHERSBURG, Md., Dec. 04, 2018 (GLOBE NEWSWIRE) --...